iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform
Provided By Globe Newswire
Last update: Apr 4, 2023
BRYAN, Texas, April 04, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced that a presentation given today by its VP & Head of Machine Learning & Platform Technologies, Matt Greving, Ph.D., during Carterra's "Unlocking High-Throughput Biology and Drug Discovery" symposium in San Diego, CA, revealed the discovery of a panel of CD3 T-cell binding antibodies, representing an important first step for the Company into bispecific immuno-oncology therapies.
0.7733
-0.06 (-6.83%)
Find more stocks in the Stock Screener
IBIO Latest News and Analysis
12 days ago - ChartmillKeep an eye on the top gainers and losers in Tuesday's session.Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
13 days ago - ChartmillThese stocks are moving in today's sessionCurious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
19 days ago - ChartmillWhich stocks are experiencing notable movement on Tuesday?Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
19 days ago - ChartmillHere are the top movers in Tuesday's session.Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
19 days ago - ChartmillWhich stocks are moving before the opening bell on Tuesday?As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
